Kymera Shares Surge 17% After Eczema Trial Finishes Enrollment Six Months Early
KYMR•Kymera Therapeutics shares jumped 17% after enrolling 200-patient midstage eczema trial six months ahead of schedule, now targeting key KT-621 results by end-2026 instead of mid-2027. The company plans to initiate late-stage eczema studies by mid-2027 pending regulatory feedback, leveraging FDA Fast Track designation.
1. Enrollment Acceleration
Kymera completed enrollment of approximately 200 adults and adolescents in its BROADEN2 Phase 2b trial for KT-621 six months earlier than planned, reflecting strong patient and physician interest in a novel oral eczema treatment.
2. Updated Trial Timeline
With enrollment ahead of schedule, Kymera now expects to report top-line results by the end of 2026 instead of mid-2027 and aims to launch late-stage atopic dermatitis trials by mid-2027, subject to regulatory clearance, under its FDA Fast Track status.
3. Market Reaction and Outlook
Shares rallied 17%, marking the best trading day in over six months, while 22 of 23 analysts maintain Buy ratings with an average price target of $120.29. The stock is up about 50% year-to-date and has seen a surge in bullish retail sentiment.
